Northern California Cattle Rancher Sues Humboldt County and Three of its Officials for Violating His Civil Rights

Alleges Former Livestock Deputy and Deputy District Attorney, with Support from Sheriff and County, Singled Him Out for Practicing Industry Standards While Ignoring Violations Elsewhere Law firm Larson LLP announced today it has sued Humboldt County and three officials in San Francisco federal court on behalf of a northern California cattle rancher, alleging they violated

New Motion Design Best Practices Guide Published by Digital Silk Web Design Agency

A new article outlining key considerations for creating effective motion design has been published by Digital Silk, an award-winning digital agency focused on creating brand strategies, custom websites and digital marketing campaigns. The resource highlights foundational elements organizations may review when integrating motion into user interfaces, product experiences and digital content. Motion design continues to

Harbor IT CFO Hannah Paige Named Finalist for CRN’s 2025 Women of the Year Rising Star Award

Harbor IT, a national cyber-first managed services provider, is proud to share that Hannah Paige, Chief Financial Officer of Harbor IT, has been named a finalist in the Rising Star of the Year category for the 2025 CRN® Women of the Year Awards, presented by The Channel Company. https://mma.prnewswire.com/media/2839139/HannahPaige3.jpg This honor recognizes Paige's exceptional impact

STUB DEADLINE ALERT: StubHub Holdings, Inc. Investors Urged to Contact Kirby McInerney LLP About Class Action Lawsuit

(NYSE:STUB), NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) — Kirby McInerney LLP reminds StubHub Holdings, Inc. (“StubHub” or the “Company”) (NYSE:STUB) investors of the January 23, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. If you purchased or otherwise acquired StubHub securities, have information, or would like

Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO Asia

(HKSE:6628), PRINCETON, N.J. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) — Transcenta Holding Limited (HKEX: 06628) (“Transcenta Therapeutics”), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announced updated efficacy analysis of Cohort G by CLDN18.2 and PD-L1 expression from the phase I/II Transtar102

Whale Cloud Receives Frost & Sullivan’s 2025 Asia-Pacific Technology Innovation Leadership Recognition for Excellence in AI-enabled OSS/BSS Solutions

Recognized for pioneering AI-driven innovation, customer-centric digital transformation, and customer experience for CSPs. Frost & Sullivanis pleased to announce that Whale Cloudhas been recognized with the 2025 Asia-Pacific Technology Innovation Leadership Recognition in the AI-enabled OSS/BSS industry for its outstanding achievements in innovation, platform integration, and customer impact. This recognition highlights Whale Cloud's consistent leadership

OTR Therapeutics Raises $100 Million in Series A Financing to Advance Early Innovation into Global Transformative Therapies

OTR Therapeutics, a biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies, emerged from stealth and announced today the successful completion of a $100 million Series A financing closed in June 2025. The round was backed by True Light Capital, a wholly-owned subsidiary of Temasek, LAV, Pfizer Ventures, and Sirona Capital. Founded in

STUB DEADLINE ALERT: StubHub Holdings, Inc. Investors Urged to Contact Kirby McInerney LLP About Class Action Lawsuit

STUB DEADLINE ALERT: StubHub Holdings, Inc. Investors Urged to Contact Kirby McInerney LLP About Class Action Lawsuit GlobeNewswire December 05, 2025 NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) — Kirby McInerney LLP reminds StubHub Holdings, Inc. (“StubHub” or the “Company”) (NYSE:STUB) investors of the January 23, 2026 deadline to seek the role of lead plaintiff

Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO Asia

Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO Asia Data showed encouraging results in patients with higher CLDN18.2 expression regardless of PD-L1 expression level, with a median PFS of 16.6 months, ORR of 68% and median DoR of 18

Scroll to Top